[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autophagy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autophagy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644843","effects-of-miricell-supplementation-on-biomarkers-of-healthy-aging-and-autophagy-100644843",false,"NCT07675200","Effects of Miricell Supplementation on Biomarkers of Healthy Aging and Autophagy","INCLUSION CRITERIA:\n\n* Provide voluntary signed and dated informed consent.\n* Be in fair health as determined by medical history and routine blood chemistries.\n* Age between the ages of 40 and 70 (inclusive).\n* Body weight of at least 110 pounds.\n* Normotensive (seated, resting systolic blood pressure \\\u003C140 mm Hg and diastolic blood pressure \\\u003C 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5-minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility.\n* Normal seated, resting heart rate (\\\u003C90 per minute).\n* Willing to duplicate their previous 24-hour diet, refrain from alcohol for 24 hours, exercise for 24 hours prior to each trial, caffeine for 12 hours prior to each trial, and fast for 10 hours prior to each of the treatments.\n* Participant agrees to maintain existing dietary and physical activity patterns throughout the study period.\n* Participant is willing and able to comply with the study protocol.\n* If a dietary supplement was initiated within the past month, the participant is willing to discontinue supplement use followed by a 2-week washout prior to participation in the study.\n* Able to provide an adequate blood draw.\n\nEXCLUSION CRITERIA:\n\n* Use of probiotics, postbiotics or antibiotics within the past month.\n* A history of unstable or new-onset cardiovascular\u002Fcardiorespiratory, liver, or renal disease.\n* The participant's alcohol consumption is more than two standard alcoholic drinks per day or more than 10 drinks per week or has a history of drug\u002Falcohol abuse or dependence.\n* History of diabetes (any form) or any endocrine disorder.\n* Fasting blood sugar of \\> 125 mg\u002FdL.\n* Current smokers who smoke 11 or more cigarettes per day (i.e. light smokers will be enrolled if they meet all other criteria).\n* History of hyperparathyroidism or an untreated thyroid disease.\n* History of malignancy in the previous five years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).\n* Chronic inflammatory condition or disease (e.g., rheumatoid arthritis, Crohn's Disease, ulcerative colitis, lupus, HIV\u002FAIDS, etc.).\n* Previous medical diagnosis of gout or fibromyalgia.\n* Any female who is pregnant, trying to become pregnant, is less than\u002For equal to 120 days postpartum, or any current women who are nursing.\n* Women who participate in this study must agree to the use of contraception for the duration of the study, and any sexually active woman will have to take a negative pregnancy test prior to enrolling. Women of childbearing age (any woman prior to menopause), regardless of their use of contraception, will be provided a urine pregnancy test kit at their screening visit and take the test in private using the female lavatory after signing an informed consent.\n* Known allergy or sensitivity to any ingredient in the test formulations as listed on the product label.\n* Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.",true,"ALL","40 Years","70 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if a dietary supplement called Miricell works to improve cellular health and signs of healthy aging in adults. It will also learn about the safety of Miricell.\n\nThe main questions it aims to answer are:\n\n* Does Miricell improve markers of autophagy, which is the body's natural process for recycling damaged cells?\n* Does Miricell support brain health, metabolic health, and visible signs of aging?\n* What medical problems, if any, do participants experience while taking Miricell?\n\nResearchers will compare Miricell to a placebo (a look-alike capsule that contains no active ingredients) to see if Miricell works better to support healthy aging.\n\nParticipants will:\n\n* Take either one Miricell capsule or a placebo every day for 12 weeks with a morning meal.\n* Visit the research clinic four times over the course of the study for checkups and tests.\n* Complete memory and thinking tests, track their daily physical activity, and give blood samples to measure health changes.",[27,28],"Autophagy","Healthy Aging",[30,31,32,33,34],"Spermidine","Polyamines","Cognitive Function","Miricell(R)","Cellular Health","RECRUITING","2026-06-23",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2026-01-09",{"date":43,"type":21},"2026-09",{"name":45,"class":46},"Nutraland USA, Inc.","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":15,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":47},"100643224","mitophagy-and-mitochondrial-dna-dynamics-during-ramadan-dry-fasting-vs-168-time-restricted-feeding-100643224","NCT07638696","Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding","Mitophagic Flux and Mitochondrial DNA Dynamics During Circadian-Aligned Ramadan Dry Fasting Versus 16:8 Time-Restricted Feeding: A Four-Phase Translational Research Programme","MITO FAST","Inclusion Criteria:\n\n* Common Criteria (Both Arms):\n* Age 18-50 years\n* BMI 18.5-30.0 kg\u002Fm²\\[cite: 1\\]\n* Non-smoker for at least 12 months\\[cite: 1\\]\n* No chronic disease requiring regular prescription medication\\[cite: 1\\]\n* Stable sleep-wake schedule (self-reported sleep midpoint deviation less than 90 minutes)\\[cite: 1\\]\n* Willing and able to attend all five study visits at the specified times\\[cite: 1\\]\n\nArm A Specific (Ramadan Dry Fasting):\n\n\\- Documented religious commitment and intention to complete all 30 days of Ramadan 2027 fasting\\[cite: 1\\]\n\nArm B Specific (16:8 TRF Control):\n\n* Confirmed practice of 16:8 TRF (fasting window 16 hours or more per day) throughout the study period\\[cite: 1\\]\n* Not observing Ramadan dry fasting during the study period\\[cite: 1\\]\n\nExclusion Criteria:\n\n* Established type 1 or type 2 diabetes (HbA1c 6.5% or higher or pharmacological antidiabetic therapy)\\[cite: 1\\]\n* Severe gastrointestinal, cardiovascular, hepatic, or renal disease (eGFR less than 60 mL\u002Fmin\u002F1.73m²)\\[cite: 1\\]\n* Active cancer or chemotherapy within five years\\[cite: 1\\]\n* Use of metformin, statins, or exogenous antioxidant supplements (vitamins C, E, NAC, CoQ10) within 30 days of screening\\[cite: 1\\]\n* Pregnancy, lactation, or planned conception during the study period\\[cite: 1\\]\n* Participation in another clinical study within three months\\[cite: 1\\]\n* Inability to provide written informed consent in Arabic or English\\[cite: 1\\]","18 Years","50 Years",{"count":59,"type":21},120,"OBSERVATIONAL","This study investigates how different types of fasting affect cell health, specifically focusing on how mitochondria (the energy-producing parts of cells) are cleared and renewed. While standard intermittent fasting allows water intake, Ramadan dry fasting involves total restriction of both food and fluids from dawn to sunset.\n\nResearchers want to see if the combined effects of fluid restriction and natural daily body rhythms during Ramadan trigger a stronger cellular cleanup process (called mitophagy) compared to standard 16:8 water-permitted fasting. The study will look at how these fasting habits change blood markers related to mitochondrial DNA and metabolic health across a 30-day period. This research will help determine if dry fasting offers distinct biological benefits for cellular renewal.",[63,27,64,65,66],"Mitochondrial Degradation","Fasting","Healthy Volunteers","Metabolic Adaptation",[68,69,70,71,72,73,74],"Ramadan fasting","Intermittent dry fasting","Time-restricted feeding","Mitochondrial DNA","Mitophagy","PBMC","PINK1-Parkin","NOT_YET_RECRUITING","2026-06-09",{"date":78,"type":39},"2026-06-11",{"date":80,"type":21},"2027-01-15",{"date":82,"type":21},"2027-04-30",{"name":84,"class":85},"Bahcesehir Cyprus University","OTHER",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":95,"conditions":96,"keywords":100,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":47},"100374822","study-of-autophagy-and-the-effects-of-galig-gene-products-in-hiv-1-infected-patients-who-are-under-antiretroviral-therapy-since-primary-infection-chronic-phase-or-never-treated-100374822","NCT04160455","Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.","ATGALIG-HIV","Inclusion Criteria:\n\nGeneral criteria:\n\n* Age \\>=18 years\n* Man or woman\n* Infected with HIV-1 (and not co-infected with HIV-2)\n* Followed at Orleans' Regional Hospital\n* Patient belonging to one of the predefined cohorts\u002Fgroups (see below)\n* Patient having provided a written consent\n\nSpecific profiles of HIV-infected patients for the ATGALIG-HIV study:\n\nCohort A: patients on suppressive antiretroviral therapy (HIV RNA \\\u003C50 copies \u002F ml for at least 4 years) initiated during the chronic phase, divided into 2 groups according to the following criteria:\n\n* group A1: CD4 count less than 500 cells \u002F ml at the time of inclusion in the study\n* group A2: CD4 count above 500 cells \u002F ml at the time of inclusion in the study Cohort B: patients on suppressive antiretroviral therapy (HIV RNA \\\u003C50 copies \u002F ml for at least 4 years) initiated since the primary-infection (within 4 months after acute infection)\n\nCohort C: patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy, divided into the following 3 groups:\n\n* group C1: HIV diagnosis made during primary infection (within 4 months of infection)\n* group C2: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count above 200 cells\u002Fml at the time of inclusion in the study\n* group C3: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count less than 200 cells\u002Fml at the time of inclusion in the study Cohort D: patients who have undetectable plasma HIV RNA (HIV RNA \\\u003C50 copies \u002F ml ) without antiretroviral therapy, either spontaneously (HIV controllers or elite controllers) or after treatment interruption (post-treatment controllers)\n\nExclusion Criteria:\n\n* Patient unable, according to the investigator, to meet the requirements of the protocol\n* Pregnant or lactating woman\n* Patient with a history of inflammatory bowel disease, malignancy, intestinal ischemia, malabsorption or other gastrointestinal dysfunction that, in the judgment of the investigator, could interfere with the interpretation of the results.\n* Presence of coagulation abnormality or unexplained bleeding history\n* Treatment with oral or injectable anticoagulant (curative or preventive)\n* Patient covered by Article L.1121-5 to L.1121-8 and L.1122-1-2 of the French Public Health Code (including minors and protected adults)\n* Patient under guardianship or curatorship\n* Patient who uncovered by French health insurance Patient participating in another clinical trial, evaluating a treatment",{"count":94,"type":21},180,"Little is known about autophagy during HIV infection. Recently, two different teams reported important dysfunctions of autophagy in HIV-infected patients despite sustained suppressive antiretroviral therapy. As altered autophagy is strongly linked to cellular senescence and chronic inflammation, two hallmarks of HIV-infected patients despite long-term suppressive antiretroviral therapy, it is important to improve our knowledge in the area.\n\nOur main objective is to determine whether all or part of mononuclear cell subpopulations (CD4+ and CD8+ T lymphocytes, and monocytes) exhibit a defect in autophagy function in a cohort of HIV-infected patients who are virologically-controlled (plasma HIV RNA \\\u003C50 copies \u002F ml) either spontaneously (i.e. HIV controllers or post-treatment controllers) or after they started antiretroviral therapy at different time points (i.e. at the acute or chronic phases), as compared with a control group (i.e. uninfected healthy blood donors).",[27,97,98,99],"Galectins","HIV Infections","Highly Active Antiretroviral Therapy",[101,102,103,104,105],"Antiretroviral therapy","basal autophagy","GALIG gene","HIV","apoptosis","2025-12-22",{"date":108,"type":39},"2025-12-30",{"date":110,"type":39},"2019-11-07",{"date":112,"type":21},"2039-11-07",{"name":114,"class":85},"Centre Hospitalier Régional d'Orléans"]